Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04227015
Other study ID # BHCT-CTA101-08
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date January 8, 2020
Est. completion date May 31, 2027

Study information

Verified date December 2020
Source Zhejiang University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy


Description:

This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory CD19+ B-line hematological malignancy: B-ALL and B-NHL. the selection of dose levels and the number of subjects are based on clinical tiral of similar foreign products. 2 groups of patients will be enrolled, 36 in each group. Primary objective is to explore the safety, main consideration is dose-related safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 72
Est. completion date May 31, 2027
Est. primary completion date January 8, 2022
Accepts healthy volunteers No
Gender All
Age group 3 Years to 70 Years
Eligibility Inclusion Criteria: Inclusion criteria applicable to ALL only: 1. Male or female aged = 3 and <70 years old; 2. Histologically confirmed diagnosis of CD19+ B-ALL per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphoblastic Leukemia (2016.v1); 3. Relapsed or refractory CD19+ B-ALL (meeting one of the following conditions): 1. CR not achieved after standardized chemotherapy; 2. CR achieved following the first induction, but CR duration is = 12 months; 3. Ineffective after first or multiple remedial treatments; 4. 2 or more recurrences; 4. The number of primordial cells (lymphoblast and prolymphocyte) in bone marrow is >5% (morphology) and/or >1% (Flow cytometry); 5. Philadelphia-chromosome-negative (Ph-) patients; or Philadelphia-chromosome-positive (Ph+) patients who cannot tolerate TKI treatments or do not respond to 2 TKI treatments; Inclusion criteria applicable to NHL only: 1. Male or female aged = 18 and <70 years old; 2. Histologically confirmed diagnosis per WHO Classification Criteria for Lymphocytic Tumors 2016, including DLBCL(NOS), follicular lymphoma, Chronic lymphoblastic leukemia/small lymphoblastic lymphoma transforms DLBCL, PMBCL and high grade B cell lymphoma; 3. Relapsed or refractory DLBCL (meeting one of the following conditions): 1. No remission or recurrence after receiving second-line or above second-line chemotherapy; 2. Primary drug resistance; 3. Recurrence after autologous hematopoietic stem cell transplantation 4. According to Lugano 2014, there should be at least one evaluable tumor lesion. Applicable standards for ALL and NHL: 1. HLA antibody(-) or HLA antibody(+) and HLA donor specific antibody(DSA)(-); 2. total bilirubin = 51umol/L, ALT and AST = 3 times of upper limit of normal, creatinine = 176.8umol/L; 3. Echocardiogram shows left ventricular ejection fraction (LVEF) = 50%; 4. No active infection in the lungs, blood oxygen saturation by sucking air is = 92%; 5. Estimated survival time = 3 months; 6. ECOG performance status 0 to 2; 7. Patients or their legal guardians volunteer to participate in the study and sign the informed consent. Exclusion Criteria: 1. patients with extramedullary lesions, except those with CNSL (CNS-1) under effective control (for ALL patients only); 2. Confirmed diagnosis of lymphoblastic crisis of chronic myeloid leukemia, Burkitt's leukemia/lymphoma per WHO Classification Criteria (for ALL patients only); 3. Patients with hereditary syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome (for ALL patients only); 4. patients with intracranial extralateral lesions (cerebrospinal fluid tumor cells and/or intracranial lymphoma invasion shown by MRI) (for NHL patients only) ; 5. extensive involvement of gastrointestinal lymphoma (for NHL patients only); 6. radiotherapy, chemotherapy and monoclonal antibody within 1 week before screening; 7. Have a history of allergy to any of the components in the cell products; 8. Prior treatment with any CAR T cell product or other genetically-modified T cell therapies; 9. According to the New York heart association (NYHA) cardiac function classification criteria, Subjects with grade III or IV cardiac insufficiency; 10. Myocardial infarction, cardioangioplasty or stenting, unstable angina pectoris, or other severe cardiac diseases within 12 months of enrollment; 11. Severe primary or secondary hypertension of grade 3 or above (WHO Hypertension Guidelines, 1999); 12. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past; 13. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases; 14. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis). 15. Indwelling catheters in vivo (e.g. percutaneous nephrostomy, Foley catheter, bile duct catheter, or pleural/peritoneal/pericardial catheter). Ommaya storage, dedicated central venous access catheters such as Port-a-Cath or Hickman catheters are allowed; 16. History of other primary cancer, except for the following conditions: 1. Cured non-melanoma after resection, such as basal cell carcinoma of the skin; 2. Cervical cancer in situ, localized prostate cancer, ductal cancer in situ with disease-free survival = 2 years after adequate treatment; 17. Patients with autoimmune diseases requiring treatment, patients with immunodeficiency or requiring immunosuppressive therapy; 18. Patients with graft-versus-host disease (GVHD); 19. Prior immunizations with live vaccine 4 weeks prior to screening; 20. History of alcoholism, drug abuse or mental illness; 21. If HBsAg positive at screening, HBV DNA copy number detected by PCR in patients with active hepatitis B > 1000 (if HBV DNA copy number=1000, routine antiviral therapy is required after enrollment), as well as CMV, hepatitis C, syphilis infection; 22. Concurrent therapy with systemic steroids within 1 week prior to screening, except for the patients recently or currently receiving inhaled steroids; 23. Patients who have participated in any other clinical studies within 2 weeks prior to screening; 24. pregnant and breast-feeding women and the subjects who are fertile and unable to take effective contraceptive measures (regardless of the gender); 25. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CTA101
CTA101 UCAR-T cell injection by intravenous infusion

Locations

Country Name City State
China The First Hospital of Zhejiang Medical Colleage Zhejiang University Hangzhou Zhejiang

Sponsors (2)

Lead Sponsor Collaborator
He Huang Nanjing Bioheng Biotech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity (DLT) Adverse events assessed according to NCI-CTCAE v5.0 criteria Baseline up to 28 days after CTA101 infusion
Primary Incidence of treatment-emergent adverse events (TEAEs) Incidence of treatment-emergent adverse events [Safety and Tolerability] Up to 2 years after CTA101 infusion
Secondary B-cell acute lymphocytic leukemia (B-ALL), MRD negative overall response rate (MRD- ORR) Assessment of MRD negative overall response rate (MRD- ORR) at 3 months after CTA101 infusion 3 months
Secondary B-ALL, Event-free survival (EFS) From the first infusion of CTA101 to the occurrence of any event, including death, relapse or gene relapse, disease progression (any one occurs first), and the last visit Month 6, 12, 18 and 24
Secondary B-ALL, Overall response rate (ORR) Assessment of ORR (ORR = CR + CRi ) at Month 6, 12, 18 and 24 Month 6, 12, 18 and 24
Secondary B-ALL, Overall survival (OS) From the first infusion of CTA101 to death or the last visit Month 6, 12, 18 and 24
Secondary B cell non-hodgkin's lymphoma (B-NHL), Overall response rate (ORR) Assessment of ORR (ORR = CR + PR ) per Lugano 2014 criteria weeks 4, 12, months 6, 12, 18 and 24
Secondary B-NHL,disease control rate (DCR) Assessment of DCR (DCR=CR+PR+SD) per Lugano 2014 criteria weeks 12, months 6, 12, 18 and 24
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT05772000 - Clinical Significance of Occult Central Nervous System Localization
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT03114865 - A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Phase 1/Phase 2
Not yet recruiting NCT06308588 - Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT05579132 - A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT02231853 - Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2
Recruiting NCT06195891 - Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome Phase 1
Withdrawn NCT02815059 - Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone Phase 1
Completed NCT00390793 - Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. Phase 2
Recruiting NCT05866887 - Insomnia Prevention in Children With Acute Lymphoblastic Leukemia N/A
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting NCT06350994 - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Not yet recruiting NCT04488237 - Vitamin D and Methotrexate Adverse Effects
Completed NCT02544438 - Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Phase 1/Phase 2